Structural asymmetry of phosphodiesterase-9a and a unique pocket for selective binding of a potent enantiomeric inhibitor

Molecular Pharmacology

Volumn 88, Issue 5, 2015, Pages 836-845

  Huang, Manna ^a   Shao, Yongxian ^a   Hou, Jianying ^a   Cui, Wenjun ^b   Liang, Beibei ^b   Huang, Yingchun ^b   Li, Zhe ^a   Wu, Yinuo ^a   Zhu, Xinhai ^a   Liu, Peiqing ^a   Wan, Yiqian ^a   Ke, Hengming ^b   Luo, Hai Bin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[1 (4 CHLOROPHENYL) ETHYL]AMINO] 1 CYCLOPENTYL 1,5,6,7 TETRAHYDRO 4H PYRAZOLO[3,4 DAY]PYRIMIDIN 4 ONE; DIMER; PHOSPHODIESTERASE; PHOSPHODIESTERASE 9A; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; CYCLIC AMP PHOSPHODIESTERASE; PDE9A PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; ENANTIOMER; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC50; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CHEMICAL PHENOMENA; CHEMISTRY; MOLECULAR GENETICS; PROTEIN MULTIMERIZATION; SPRAGUE DAWLEY RAT; STEREOISOMERISM;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DESIGN; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MALE; MOLECULAR SEQUENCE DATA; PHOSPHODIESTERASE INHIBITORS; PROTEIN MULTIMERIZATION; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 84946546463     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.099747     Document Type: Article

References (42)

1. Agranat I, Caner H, and Caldwell J (2002) Putting chirality to work: The strategy of chiral switches. Nat Rev Drug Discov 1:753-768.
2. Claffey MM, Helal CJ, Verhoest PR, Kang Z, Fors KS, Jung S, Zhong J, Bundesmann MW, Hou X, and Lui S et al. (2012) Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors. J Med Chem 55:9055-9068.
3. Conti M and Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511.
4. Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, and Visser MS et al. (2009) The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett 19:2537-2541.
5. Emsley P, Lohkamp B, Scott WG, and Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501.
6. Heckman PRA, Wouters C, and Prickaerts J (2015) Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: A translational overview. Curr Pharm Des 21:317-331.
7. Hou J, Xu J, Liu M, Zhao R, Luo HB, and Ke H (2011) Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine. PLoS One 6:e18092.
8. Huai Q, Wang H, Sun Y, Kim HY, Liu Y, and Ke H (2003) Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure 11:865-873.
9. Huai Q, Wang H, Zhang W, Colman RW, Robinson H, and Ke H (2004) Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3- isobutyl-1-methylxanthine binding. Proc Natl Acad Sci USA 101:9624-9629.
10. Hutson PH, Finger EN, Magliaro BC, Smith SM, Converso A, Sanderson PE, Mullins D, Hyde LA, Eschle BK, and Turnbull Z et al. (2011) The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S, 4S)-4-methyl-1-(pyrimidin-2-ylmethyl) pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1, 5-dihydro-4H-pyrazolo[3, 4-d]pyrimidin-4- one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 61:665-676.
11. Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, Grimwood S, Guanowsky V, Hajós M, and Harms JF et al. (2012) Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J Pharmacol Exp Ther 341:396-409.
12. Kroker KS, Mathis C, Marti A, Cassel JC, Rosenbrock H, and Dorner-Ciossek C (2014) PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. Neurobiol Aging 35:2072-2078.
13. Kroker KS, Rast G, Giovannini R, Marti A, Dorner-Ciossek C, and Rosenbrock H (2012) Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP. Neuropharmacology 62: 1964-1974.
14. Liddie S, Anderson KL, Paz A, and Itzhak Y (2012) The effect of phosphodiesterase inhibitors on the extinction of cocaine-induced conditioned place preference in mice. J Psychopharmacol 26:1375-1382.
15. Liu S, Mansour MN, Dillman KS, Perez JR, Danley DE, Aeed PA, Simons SP, Lemotte PK, and Menniti FS (2008) Structural basis for the catalytic mechanism of human phosphodiesterase 9. Proc Natl Acad Sci USA 105:13309-13314.
16. Londesborough J (1985) Evidence that the peripheral cyclic AMP phosphodiesterase of rat liver plasma membranes is a metalloenzyme. Biochem J 225:143-147.
17. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, and Manganiello VC (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13: 290-314.
18. Meng F, Hou J, Shao YX, Wu PY, Huang M, Zhu X, Cai Y, Li Z, Xu J, and Liu P et al. (2012) Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design. J Med Chem 55:8549-8558.
19. Mentel M, Blankenfeldt W, and Breinbauer R (2009) The active site of an enzyme can host both enantiomers of a racemic ligand simultaneously. Angew Chem Int Ed Engl 48:9084-9087.
20. Nagy D, Tingley FD 3rd, Stoiljkovic M, and Hajós M (2015) Application of neurophysiological biomarkers for Huntington's disease: evaluating a phosphodiesterase 9A inhibitor. Exp Neurol 263:122-131.
21. Otwinowski Z and Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
22. Schwam EM, Nicholas T, Chew R, Billing CB, Davidson W, Ambrose D, and Altstiel LD (2014) A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr Alzheimer Res 11:413-421.
23. Sekhon BS (2013) Exploiting the power of stereochemistry in drugs: An overview of racemic and enantiopure drugs. J Mod Med Chem 1:10-36.
24. Shaner NC, Steinbach PA, and Tsien RY (2005) A guide to choosing fluorescent proteins. Nat Methods 2:905-909.
25. Shao YX, Huang M, Cui W, Feng LJ, Wu Y, Cai Y, Li Z, Zhu X, Liu P, and Wan Y et al. (2014) Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent. J Med Chem 57:10304-10313.
26. Singh N and Patra S (2014) Phosphodiesterase 9: insights from protein structure and role in therapeutics. Life Sci 106:1-11.
27. van der Staay FJ, Rutten K, Bärfacker L, Devry J, Erb C, Heckroth H, Karthaus D, Tersteegen A, van Kampen M, and Blokland A et al. (2008) The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 55:908-918.
28. Vardigan JD, Converso A, Hutson PH, and Uslaner JM (2011) The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task. J Neurogenet 25:120-126.
29. Venkatachalam CM, Jiang X, Oldfield T, and Waldman M (2003) LigandFit: A novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 21:289-307.
30. Verhoest PR, Fonseca KR, Hou X, Proulx-Lafrance C, Corman M, Helal CJ, Claffey MM, Tuttle JB, Coffman KJ, and Liu S et al. (2012) Design and discovery of 6-[(3S, 4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1- (tetrahydro-2H-pyran-4-yl)-1, 5-dihydro-4H-pyrazolo[3, 4-d]pyrimidin-4-one (PF- 04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. J Med Chem 55:9045-9054.
31. Verhoest PR, Proulx-Lafrance C, Corman M, Chenard L, Helal CJ, Hou X, Kleiman R, Liu S, Marr E, and Menniti FS et al. (2009) Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. J Med Chem 52:7946-7949.
32. Wang H, Kunz S, Chen G, Seebeck T, Wan Y, Robinson H, Martinelli S, and Ke H (2012) Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and implications for design of parasite selective inhibitors. J Biol Chem 287:11788-11797.
33. Wang H, Liu Y, Chen Y, Robinson H, and Ke H (2005) Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J Biol Chem 280:30949-30955.
34. Wang H, Liu Y, Hou J, Zheng M, Robinson H, and Ke H (2007a) Structural insight into substrate specificity of phosphodiesterase 10. Proc Natl Acad Sci USA 104: 5782-5787.
35. Wang H, Liu Y, Huai Q, Cai J, Zoraghi R, Francis SH, Corbin JD, Robinson H, Xin Z, and Lin G et al. (2006) Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem 281: 21469-21479.
36. Wang H, Luo X, Ye M, Hou J, Robinson H, and Ke H (2010) Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis. J Med Chem 53:1726-1731.
37. Wang H, Yan Z, Geng J, Kunz S, Seebeck T, and Ke H (2007b) Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors. Mol Microbiol 66:1029-1038.
38. Wang H, Yan Z, Yang S, Cai J, Robinson H, and Ke H (2008a) Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. Biochemistry 47:12760-12768.
39. Wang H, Ye M, Robinson H, Francis SH, and Ke H (2008b) Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol 73: 104-110.
40. Winn MD, Murshudov GN, and Papiz MZ (2003) Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol 374:300-321.
41. Wu G, Robertson DH, Brooks CL 3rd, and Vieth M (2003) Detailed analysis of gridbased molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 24:1549-1562.
42. Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, and Hendrix M (2005) Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 68:1775-1781.